Cadrenal Therapeutics (CVKD) Research & Development (2022 - 2026)
Cadrenal Therapeutics (CVKD) posted Research & Development of $784646.0 for Q3 2024, down 37.41% sequentially from $1.3 million in Q2 2024, and up 221.64% YoY from $243948.0 in Q4 2023.
Cadrenal Therapeutics (CVKD) Research & Development (2022 - 2026) Analysis & Trends
Cadrenal Therapeutics has reported Research & Development for 3 years, with the latest figure at $784646.0 in Q3 2024.
- Quarterly Research & Development rose 221.64% year-over-year to $784646.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $3.0 million (down 25.59% YoY) and the FY2023 annual result came in at $4.1 million, up 938.88% from the prior year.
- Research & Development declined to $784646.0 in Q3 2024 per CVKD's latest filing, from $1.3 million in the prior quarter.
- Over five years, Research & Development peaked at $3.2 million in Q1 2023 and troughed at $17860.0 in Q1 2022.
- A 3-year average of $670457.4 and a median of $349817.0 in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development jumped 18014.88% in 2023, then tumbled 80.56% in 2024.
- Over 3 years, Research & Development stood at $349817.0 in 2022, then increased by 3.23% to $361127.0 in 2023, then jumped by 117.28% to $784646.0 in 2024.
- According to Business Quant data, Research & Development over the past three periods registered $784646.0, $1.3 million, and $629025.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 97.90 Mn |
| 10 | Cadrenal Therapeutics | 4.69 Mn | 2.29 Mn | - | 705,151.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 705,151.00 |
| Jun 30, 2025 | 1.08 Mn |
| Sep 30, 2024 | 784,646.00 |
| Jun 30, 2024 | 1.25 Mn |
| Mar 31, 2024 | 629,025.00 |
| Dec 31, 2023 | 361,127.00 |
| Sep 30, 2023 | 243,948.00 |
| Jun 30, 2023 | 240,957.00 |
| Mar 31, 2023 | 3.24 Mn |
| Dec 31, 2022 | 349,817.00 |
| Sep 30, 2022 | 56,388.00 |
| Jun 30, 2022 | 202,235.00 |
| Mar 31, 2022 | 17,860.00 |